Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Dow
McKesson
Johnson and Johnson
Moodys

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR LANOXIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lanoxin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Abbott Medical Devices N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Duke Clinical Research Institute N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed St. Jude Medical N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Mayo Clinic N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00723424 ↗ Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin Completed AstraZeneca Phase 1 2008-07-01 The purpose of the study is to examine the effect of AZD5672 (dosed to steady state) on the pharmacokinetics of digoxin (single dose administration).
NCT00831506 ↗ Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects Completed Medivation, Inc. Phase 1 2009-02-01 This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.
NCT00831506 ↗ Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects Completed Pfizer Phase 1 2009-02-01 This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lanoxin

Condition Name

Condition Name for Lanoxin
Intervention Trials
Healthy 7
Atrial Fibrillation 2
Steatohepatitis Caused by Ingestible Alcohol 1
Chemical and Drug Induced Liver Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lanoxin
Intervention Trials
Atrial Fibrillation 2
Emergencies 1
Fatty Liver 1
Heart Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lanoxin

Trials by Country

Trials by Country for Lanoxin
Location Trials
United States 19
France 1
Belgium 1
Sweden 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lanoxin
Location Trials
Texas 2
Connecticut 2
Illinois 2
California 2
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lanoxin

Clinical Trial Phase

Clinical Trial Phase for Lanoxin
Clinical Trial Phase Trials
Phase 4 1
Phase 2 2
Phase 1 11
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lanoxin
Clinical Trial Phase Trials
Completed 13
Recruiting 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lanoxin

Sponsor Name

Sponsor Name for Lanoxin
Sponsor Trials
AstraZeneca 2
Bristol-Myers Squibb 2
White, Katharine O'Connell, M.D., M.P.H. 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lanoxin
Sponsor Trials
Industry 16
Other 12
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Baxter
McKesson
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.